Nanobiotix NBTX
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 11th percentile, 5-year average -11.9x
Near the bottom of its 5-year range · 9th percentile, 5-year average -9.3x
Above its usual level · 67th percentile, 5-year average 9,270.7x
#4995 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | -42.46 | – | -9.33 | 9% (cheaper than usual) | – |
| PE | -25.52 | -100.69 | -11.94 | 11% (cheaper than usual) | – |
| PS | 169.56 | 38.40 | 9,270.69 | 67% (pricier than usual) | #4995 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on NBTX.
Sign in to join the discussion.